[ad_1]
A Cardiff University study finds that mouthwash containing 0.07 percent cetypyridinium chloride can fight coronavirus.
Over-the-counter mouthwash can kill the coronavirus within 30 seconds of exposure, according to a study.
Scientists at Cardiff University found that a mouthwash containing at least 0.07 percent cetylpyridinium chloride (CPC) showed “promising signs” of reducing transmission of the virus.
Their preliminary report, which has not yet been peer-reviewed, supports a study published last week that found that CPC-containing mouthwash helps reduce the viral load of people infected with the coronavirus.
It comes before a clinical trial in patients at the University Hospital of Wales in Cardiff to find out if mouthwash can reduce the coronavirus in a patient’s saliva. The findings are expected to be published in early 2021.
Dentyl is the only UK mouthwash brand to be part of the clinical trial led by Professor David Thomas of Cardiff University.
“Although this in vitro study is very encouraging and a positive step, more clinical research is now needed,” Dr. Thomas told the PA news agency, as quoted by the Independent newspaper.
“We need to understand whether the effect of OTC mouthwashes on the COVID-19 virus achieved in the laboratory can be replicated in patients, and we hope to complete our clinical trial in early 2021.”
A breath of fresh air
Dr Nick Claydon, a specialist periodontologist, said he believed that mouthwash can become an important addition to the fight against coronavirus alongside “hand washing, physical distancing and the use of masks, both now and in the future”.
There are more than 54 million confirmed COVID-19 cases worldwide and restrictions have been increased in the US and Europe to curb spiraling infections.
There is promising news from the race for a COVID-19 vaccine, as the American biotech firm Moderna said Monday that preliminary data from an ongoing phase three study of its experimental vaccine showed it to be 94.5 percent effective.
The news followed last week’s announcement by US pharmaceutical giant Pfizer that results from phase three of the COVID-19 vaccine trial it is developing with Germany’s BioNTech showed that it is more than 90 percent effective.
[ad_2]
